2010
DOI: 10.1111/j.1464-410x.2009.09088.x
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Prostate‐specific antigen (PSA) has been used for detecting prostate cancer since 1994. Although it is the best cancer biomarker available, PSA is not perfect. It lacks both the sensitivity and specificity to accurately detect the presence of prostate cancer. None of the PSA thresholds currently in use consistently identify patients with prostate cancer and exclude patients without cancer. Novel approaches to improve our ability to detect prostate cancer and predict the course of the disease are needed. Additi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
35
0
2

Year Published

2010
2010
2018
2018

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 41 publications
(37 citation statements)
references
References 26 publications
0
35
0
2
Order By: Relevance
“…Genomic-based classification offers the hope of more informed clinical decision-making and may yield novel therapeutic targets. To date, several potential biomarkers including prostate cancer gene 3, methylation, human kallikrein 2, prostate-specific membrane antigen have been identified for the detection of PCa through molecular, biological, and genetic studies, but their predictive value remains to be conclusively verified [6-9]. …”
Section: Introductionmentioning
confidence: 99%
“…Genomic-based classification offers the hope of more informed clinical decision-making and may yield novel therapeutic targets. To date, several potential biomarkers including prostate cancer gene 3, methylation, human kallikrein 2, prostate-specific membrane antigen have been identified for the detection of PCa through molecular, biological, and genetic studies, but their predictive value remains to be conclusively verified [6-9]. …”
Section: Introductionmentioning
confidence: 99%
“…However, the low specificity of this test has led to overtreatment of early and less aggressive cancer and under-treatment of indolent but aggressive cancer, leading to high morbidity [2]. In addition, current treatments have high morbidity and possible post-treatment relapses, which compromise the patient's quality of life and survival [3], [4].…”
Section: Introductionmentioning
confidence: 99%
“…These limitations have spurred interest in other molecular parameters that could be used for more accurate, noninvasive diagnosis of PCa. To date, several potential biomarkers for the detection of PCa have been identified through molecular, biological, and genetic studies, but their predictive value remains to be conclusively verified (4)(5)(6)(7)(8).…”
Section: Introductionmentioning
confidence: 99%